Hjem
  • E-postThomas.Arnesen@uib.no
  • Telefon+47 55 58 66 94
  • Besøksadresse
    Jonas Lies vei 91
  • Postadresse
    Postboks 7804
    5020 Bergen

Mitt laboratorium ved Universitetet i Bergen studerer molekylærbiologi av protein N-terminale acetylering og N-terminale acetyltransferaser (NATs).

Våre mål spenner fra å definere molekylære mekanismer for N-terminal acetylering for å etablere sammenhenger mellom NAT-defekter eller NAT-overekspresjon og sykdommer som kreft og sjeldne syndromer.

Vi har bland annet avslørt hvor viktig NatA er for kreftcellens overlevelse, og identifisert de første genetiske lidelsene forårsaket av NAT-mutasjoner.

Peer reviewed publications (chronological order):

69. Varland S, Myklebust LM, Strømsøy S, Glomnes N, Torsvik J, Varhaug JE, Arnesen T (2018) Identification of an alternatively spliced nuclear isoform of human N-terminal acetyltransferase Naa30 Gene 644:27-37. 

68. Grytaas MA, Strømsøy SS, Rørvik JT, Arnes JB, Heie A, Arnesen T, Jørstad MD, Nedrebø BG, Jøssang DE, Jensen DK, Rørvik HD, Sagen JV, Mellgren G, Thordarson HB, Husebye ES, Løvås K (2017) Clinical Characteristics and Long-Term Outcome of Primary Aldosteronism in a Norwegian Population Horm Metab Res 49(11):838-846.

67. Starheim KK, Kalvik T, Bjørkøy G, Arnesen T (2017) Depletion of the human N-terminal acetyltransferase hNaa30 disrupts Golgi integrity and ARFRP1-localization Biosci Rep 37(2). pii: BSR20170066.

66. Aksnes H, Goris M, Strømland Ø, Drazic A, Waheed Q, Reuter N, Arnesen T (2017) Molecular determinants of the N-terminal acetyltransferase Naa60 anchoring to the Golgi membrane J Biol Chem 292(16):6821-6837.

65. Foyn H, Thompson PR, Arnesen T (2017) DTNB-Based quantification of in vitro enzymatic N-terminal acetyltransferase activity Methods Mol Biol 1574:9-15.

64. Drazic A, Arnesen T (2017) [14C]-acetyl-coenzymeA-based in vitro N-terminal acetylation assay Methods Mol Biol 1574:1-8.

63. Ribeiro AL, Silva RD, Foyn H, Tiago MN, Rathore OS, Arnesen T, Martinho RG (2016) Naa50/San-dependent N-terminal acetylation of Scc1 is potentially important for sister chromatid cohesion Sci Rep 6:39118.

62. Van Damme P, Kalvik TV, Starheim KK, Jonckheere V, Myklebust LM, Menschaert G, Varhaug JE, Gevaert K, Arnesen T (2016) A role for human N-terminal acetyltransferase Naa30 in maintaining mitochondrial integrity. Mol Cell Proteomics 15(11):3361-3372.

61. Osberg C, Aksnes H, Ninzima S, Marie M, Arnesen T (2016) Microscopy-based Saccharomyces cerevisiae complementation model reveals functional conservation and redundancy of N-terminal acetyltransferases. Sci Rep 6:31627.

60. Aksnes H, Drazic A, Marie M, Arnesen T (2016) First Things First: Vital Protein Marks by N-Terminal Acetyltransferases. Trends Biochem Sci 41(9):746-60.

59. Støve SI, Magin R, Foyn H, Haug BE, Marmorstein R, Arnesen T (2016) Crystal structure of the Golgi-associated human N-alpha acetyltransferase 60 reveals the molecular determinants for substrate-specific acetylation. Structure 24(7):1044-56.

58. Drazic A, Myklebust LM, Ree R, Arnesen T (2016) The world of protein acetylation.Biochim Biophys Acta 1864(10):1372-401.

57. Saunier C, Støve SI, Popp B, Gérard B, Blenski M, AhMew N, de Bie C, Goldenberg P, Isidor B, Keren B, Leheup B, Lampert L, Mignot C, Tezcan K, Mancini GM, Nava C, Wasserstein M, Bruel AL, Thevenon J, Masurel A, Duffourd Y, Kuentz P, Huet F, Rivière JB, van Slegtenhorst M, Faivre L, Piton A, Reis A, Arnesen T, Thauvin-Robinet C, Zweier C (2016) Expanding the Phenotype Associated with NAA10 Related N-terminal Acetylation Deficiency. Hum Mutat 37(8):755-64.

56. Casey JP, Støve SI, McGorrian C, Galvin J, Blenski M, Dunne A, Ennis S, Brett F, King MD, Arnesen T, Lynch SA (2015) NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment. Sci Rep 5:16022. 

55. Myklebust LM, Støve SI, Arnesen T (2015) Naa10 in development and disease.Oncotarget 6(33):34041-2.

54. Ree RM, Myklebust LM, Thiel P, Foyn H, Fladmark KE, Arnesen T (2015) The N-terminal acetyltransferase Naa10 is essential for zebrafish development. Biosci Rep 35(5). pii: e00249.

53. Linster E, Stephan I, Bienvenut WV, Maple-Grødem J, Myklebust LM, Huber M, Reichelt M, Sticht C, Geir Møller S, Meinnel T, Arnesen T, Giglione C, Hell R, Wirtz M (2015) Downregulation of N-terminal acetylation triggers ABA-mediated drought responses in Arabidopsis. Nature Commun 6:7640.

52. Aksnes H, Marie M, Arnesen T (2015) Holding it together: Naa60 at the Golgi.Oncotarget 6(18):15726-7.

51. Aksnes H, Drazic A, Arnesen T (2015) (Hyper)tension release by N-terminal acetylation.Trends Biochem Sci 40(8):422-4.

50. Varland S, Osberg C, Arnesen T (2015) N-terminal modifications of cellular proteins: the enzymes involved, their substrate specificities and biological effects. Proteomics15(14):2385-401.

49. Van Damme P, Hole K, Gevaert K, Arnesen T (2015) N-terminal acetylome analysis reveals the specificity of Naa50 (Nat5) and suggests a kinetic competition between N-terminal acetyltransferases and methionine aminopeptidases. Proteomics 15(14):2436-46.

48. Aksnes H, Van Damme P, Goris M, Starheim KK, Marie M, Støve SI, Hoel C, Kalvik TV, Hole K, Glomnes N, Furnes C, Ljostveit S, Ziegler M, Niere M, Gevaert K, Arnesen T (2015) An Organellar N-alpha Acetyltransferase, Naa60, Acetylates Cytosolic N-termini of Transmembrane Proteins and Maintains Golgi Integrity. Cell Rep 10(8):1362-74. 

47. Myklebust LM, Van Damme P, Støve SI, Dörfel MJ, Abboud A, Kalvik TV, Grauffel C, Jonckheere V, Wu Y, Swensen J, Kaasa H, Liszczak G, Marmorstein R, Reuter N, Lyon GJ, Gevaert K, Arnesen T (2015) Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. Hum Mol Genet 24(7):1956-76.

46. Aksnes H, Hole K, Arnesen T (2015) Molecular, Cellular, and Physiological Significance of N-Terminal Acetylation. Int Rev Cell Mol Biol 316:267-305.

45. Popp B, Støve SI, Endele S, Myklebust LM, Hoyer J, Sticht H, Azzarello-Burri S, Rauch A, Arnesen T, Reis A (2015) De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females. Eur J Hum Genet 23(5):602-9.

44. Van Damme P, Støve SI, Glomnes N, Gevaert K, Arnesen T (2014) A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase Naa10S37P mutant. Mol Cell Proteomics 13(8):2031-41.

43. Dutta RK, Welander J, Brauckhoff M, Arnesen T, Alesina P, Walz M, Söderkvist P, Gimm O (2014) Complementary somatic mutations in sporadic aldosterone producing adrenal adenomas Endocr Relat Cancer ERC 21(1):L1-4. 

42. Liszczak G, Goldberg JM, Foyn H, Petersson EJ, Arnesen T, Marmorstein R (2013) Molecular basis for N-terminal acetylation by the heterodimeric NatA complex. Nature Struct Mol Biol 20(9):1098-105.

41. Arnesen T, Glomnes N, Strømsøy S, Knappskog S, Heie A, Akslen LA, Grytaas M, Varhaug JE, Gimm O, Brauckhoff M (2013) Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population based study from Western Norway. Langenbecks Arch Surg 398(6):869-74.

40. Aksnes H, Osberg C, Arnesen T (2013) N-Terminal Acetylation by NatC Is Not a General Determinant for Substrate Subcellular Localization in Saccharomyces cerevisiae. PLOS ONE8(4): e61012.

39. Foyn H, Jones JE, Lewallen D, Narawane R, Varhaug JE, Thompson PR, Arnesen T (2013) Design, Synthesis, and Kinetic Characterization of Protein N-Terminal Acetyltransferase Inhibitors. ACS Chem Biol 8:1121–1127.

38. Evjenth R, Van Damme P, Gevaert K, Arnesen T (2013) HPLC-based Quantification of in vitro N-terminal Acetylation. Methods Mol Biol 981:95-102.

37. Van Damme P, Arnesen T, Ruttens B, Gevaert K (2013) In-gel N-acetylation for the Quantification of the Degree of Protein in vivo N-terminal Acetylation. Methods Mol Biol981:115-26. 

36. Foyn H, Van Damme P, Støve S, Glomnes N, Evjenth R, Gevaert K, Arnesen T (2013) Protein N-Terminal acetyltransferases act as N-Terminal propionyltransferases in vitro and in vivo. Mol Cell Proteomics 12:42-54. Covered by ASBMB news. 

35. Kalvik TV and Arnesen T (2013) Protein N-terminal acetyltransferases in cancer.Oncogene 32(3):269-76.

34. Grauffel C, Abboud A, Liszczak G, Marmorstein R, Arnesen T, Reuter N (2012) Specificity and Versatility of Substrate Binding Sites in Four Catalytic Domains of Human N-Terminal Acetyltransferases. PLoS ONE 7(12): e52642

33. Van Damme P, Lasa M, Polevoda B, Gazquez C, Elosegui-Artola A, Kim DS, De Juan-Pardo E, Demeyer K, Hole K, Larrea E, Timmerman E, Prieto J, Arnesen T, Sherman F, Gevaert K, Aldabe R (2012) N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci USA 109(31):12449-54.

32. Starheim KK, Gevaert K, Arnesen T (2012) Protein N-terminal acetyltransferases: when the start matters. Trends Biochem Sci 37(4):152-61.

31. Evjenth R, Brenner A, Thompson PR, Arnesen T, Frøystein NÅ, Lillehaug JR (2012) The human protein N-terminal acetyltransferase hNaa50p (hNat5/hSan) follows an ordered sequential catalytic mechanism: A combined kinetic and NMR study. J Biol Chem287(13):10081-8. 

30. Liszczak G, Arnesen T, Marmorstein R (2011) Structure of a ternary Naa50p (NAT5/San) Nα-terminal Acetyltransferase complex reveals the molecular basis for substrate specific acetylation. J Biol Chem 286(42):37002-10.

29. Hole K, Van Damme P, Dalva M, Aksnes H, Glomnes N, Varhaug J, Lillehaug JR, Gevaert K, Arnesen T (2011) The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is conserved from yeast and N-terminally acetylates histones H2A and H4. PLoS ONE 6(9): e24713. 

28. Van Damme P, Hole K, Pimenta-Marques A, Helsens K, Vandekerckhove J, Martinho RG, Gevaert K, Arnesen T (2011) NatF Contributes to an Evolutionary Shift in Protein N-Terminal Acetylation and Is Important for Normal Chromosome Segregation. PLoS Genet 7(7): e1002169.

27. Van Damme P, Arnesen T, Gevaert K (2011) Protein alpha-N-acetylation studied by N-terminomics. FEBS J 278(20):3822-34. 

26. Rope A, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ, Johnson WE, Moore B, Huff CD, Bird LM, Carey JC, Opitz JM, Stevens CA, Jiang T, Schank C, Fain HD, Robison R, Dalley B, Chin S, South ST, Pysher TJ, Jorde LB, Hakonarson H, Lillehaug JR, Biesecker LB, Yandell M, Arnesen T, Lyon GJ (2011) Using VAAST to Identify an X-Linked Disorder Resulting in Lethality in Male Infants Due to N-Terminal Acetyltransferase Deficiency. Am J Hum Genet89(1):28-43. Comment in Nature News: doi:10.1038/news.2011.382 

25. Arnesen T. (2011) Towards a functional understanding of protein N-terminal acetylation.PLoS Biology 9(5): e1001074.

24. Helsens K, Van Damme P, Degroeve S, Martens L, Arnesen T, Vandekerckhove J, Gevaert K. (2011) Bioinformatics analysis of a Saccharomyces cerevisiae N-terminal proteome provides evidence of alternative translation initiation and post-translational N-terminal acetylation. J Proteome Res 10(8):3578-3589. 

23. Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock P-J, Lillehaug JR, Vandekerckhove J, Arnesen T, Gevaert K. (2011) Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of Nα-acetyltransferases and point to hNaa10p as the posttranslational actin Nα-acetyltransferase. Mol Cell Proteomics 10: M110.004580. 

22. Gromyko D, Arnesen T, Ryningen A, Varhaug JE, Lillehaug JR (2010) Depletion of the human N-terminal acetyltransferase A (hNatA) induces p53-dependent apoptosis and p53-independent growth inhibition. Int J Cancer 127(12):2777-89.

21. Arnesen T, Starheim KK, Van Damme P, Evjenth R, Dinh H, Betts M, Ryningen A, Vandekerckhove J, Gevaert K, Anderson D. (2010) The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation. Mol Cell Biol 30(8):1898-909.

20. Evjenth R, Hole K, Karlsen OA, Ziegler M, Arnesen T, Lillehaug JR (2009) Human Naa50 (Nat5/San) displays both protein N-alpha and N-epsilon acetyltransferase activity. J Biol Chem. 284(45):31122-9.

19. Starheim KK, Gromyko D, Velde R, Varhaug JE, Arnesen T. (2009) Composition and biological significance of the human Nα-terminal acetyltransferases. BMC Proc. 3 (Suppl 6):S3

18. Polevoda B, Arnesen T, Sherman F. (2009) A synopsis of eukaryotic Nα-terminal acetyltransferases: nomenclature, subunits and substrates. BMC Proc. 3 (Suppl 6):S2.  

17. Arnesen T. (2009) Protein N-terminal acetylation: NAT 2007–2008 Symposia. BMC Proc. 3 (Suppl 6):S1.

16. Takubo K, Tsuchiya H, Kurimasa A, Arnesen T, Ryoke K, Shiota G. (2009) Involvement of N-acetyltransferase human in the cytotoxic activity of 5-fluorouracil. Anti-Cancer Drugs.20:668-75.

15. Arnesen T, Gromyko D, Kagabo D, Betts MJ, Varhaug JE, Anderson D, Lillehaug JR. (2009) A novel human NatA Nα-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1). BMC Biochem. 10:15.

14. Starheim K, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR, Arnesen T. (2009) Knockdown of the human NatC protein Nα-terminal acetyltransferase complex induces p53-mediated apoptosis and aberrant hArl8b localization. Mol Cell Biol 29(13):3569-81.   

13. Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N, Varhaug JE, Vandekerckhove J, Lillehaug JR, Sherman F, Gevaert K. (2009) Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci USA. 106:8157-8162. 

12. Målen H, Lillehaug JR, Arnesen T. (2009)The protein Nα-terminal acetyltransferase hNaa10p (hArd1) is phosphorylated in HEK293 cells. BMC Res Notes2:32.

11. Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR. (2008) The protein acetyltransferase ARD1 – a novel cancer drug target? Curr Cancer Drug Targets. 8:545-553.

10. Starheim K, Arnesen T, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR. (2008) Identification of the human Na-acetyltransferase complex B (hNatB) – a complex important for cell cycle  progression. Biochemical J 415:325-331.

9. Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lønning PE. (2006) A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes Chr. Cancer.45(12):1155-63.  

8. Arnesen T, Betts M, Pendino F, Liberles D, Anderson D, Caro J, Kong X, Varhaug JE, Lillehaug JR. (2006) Characterization of hARD2, a processed hARD1 gene duplicate encoding a human protein N-α-acetyltransferase. BMC Biochem 7:13.

7. Arnesen T. (2006) HIF-1α and ARD1: enemies, friends or neither? Nat Rev Cancer. 6 (3): doi:10.1038/nrc1779-c1.

6. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR. (2006) Induction of apoptosis in human cells by RNAi mediated knock-down of hARD1 and NATH, components of the protein N-α-acetyltransferase complex. Oncogene 25:4350-4360. 

5. Arnesen T, Anderson D, Torsvik J, Varhaug JE, Lillehaug JR. (2006) Cloning and characterization of hNAT5/hSAN: An evolutionary conserved component of the NatA protein N-α-acetyltransferase complex. Gene 371:291-295.

4. Arnesen T, Kong X, Evjenth R, Gromyko D, Varhaug JE, Lin Z, Sang N, Caro J, Lillehaug JR. (2005) Interaction between HIF-1α (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1α. FEBS Lett 579(28):6428-32.

3. Arnesen T, Gromyko D, Horvli O, Fluge Ø, Lillehaug JR, Varhaug JE (2005) Expression of NATH and hARD1 proteins in thyroid neoplasms. Thyroid 15(10):1131-6.

2. Furnes C, Arnesen T, Askjaer P, Kjems J, Szilvay AM. (2005) HIV-1 Rev oligomerization is not obligatory in the presence of an extra basic domain. Retrovirology 2(1):39.

1. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR. (2005) Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochemical J 386(Pt 3):433-43.

Publications in national current research information system (CRIStin)

2016 Professor/Group leader, Department of Molecular Biology, University of Bergen

2016 Senior investigator, Norwegian Cancer Society

2015 Young associate investigator, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership Molecular Medicine

2012 Researcher/Group leader (Bergen Research Foundation BFS) Department of Molecular Biology, University of Bergen.

2010 Researcher, Department of Surgery, Haukeland University Hospital

2010-2013 Researcher/Principal Investigator (Research Council of Norway), University of Bergen, Norway

2009-2009 Associate Professor, University of Bergen, Norway

2006-2009 Post Doc (Norwegian Health Authorities West) University of Bergen, Norway (Prof. JE Varhaug and Prof. JR Lillehaug) and University of Rochester, USA (Prof. Fred Sherman)

2006 Ph.D. Molecular Biology (Norwegian Cancer Society), University of Bergen, Norway (Prof. JE Varhaug and Prof. JR Lillehaug)

2002 Cand. scient. (M.Sc.) Molecular Biology, University of Bergen, Norway  (Prof. AM Szilvay)

1999 Biomedical Laboratory Scientist (B.Sc.) Bergen University College, Norway